ELDN

1.7806.32%
JA

James A. Robinson

Independent Director

Mr. James A. Robinson, Jr., also known as Jim, is Chief Executive Officer and Director of A2 Biotherapeutics, Inc. from April 1, 2024. He is Director of Petauri Health, LLC from December 2023. He serves as an Independent Director at Eledon Pharmaceuticals, Inc. since October 01, 2023. He is Independent Director at UroGen Pharma Ltd. from July 26, 2023. He serves as an Independent Director at Applied Genetic Technologies Corporation since November 2021. He had been Independent Director of Urovant Sciences Ltd. Since March 6, 2019 until June 2023 and was its Chief Executive Officer since March 23, 2020 until June 2023. As Chief Executive Officer and Director of Urovant Sciences, Mr. Robinson guided the company through FDA approval of its first drug, a successful product launch and its acquisition and take-private transaction by Sumitomo Dainippon Pharma. Mr. Robinson had been President of Urovant Sciences Ltd. since June 2020 until June 2023. From April 2019 to March 2020, Mr. Robinson served as President and Chief Operating Officer at Paragon Biosciences, where he oversaw Paragons operations and also served as the Chief Executive Officer of Qlarity Imaging, a Paragon portfolio company. He served as the President and Chief Operating Officer of Alkermes plc from March 5, 2018 to April 19, 2019, where he was responsible for global commercial operations, new product planning, corporate planning, manufacturing, quality, human resources and business development. Mr. Robinson had been an Independent Director at Neos Therapeutics, Inc. since January 29, 2019 until March 19, 2021. He serves as Director of Chicago Botanic Garden. Mr. Robinson has biopharmaceutical industry experience spanning a variety of diverse disciplines, including sales, marketing, new product planning, market access, reimbursement and government affairs. Prior to that, he served as the President of Americas Operations at Astellas US, LLC from April 01, 2016 to March 5, 2018. Mr. Robinson served as the President of Americas Operations at Astellas Pharma, Inc. from April 1, 2016 to March 5, 2018. Mr. Robinson served as the President of Astellas Pharma US, Inc. until March 5, 2018. Mr. Robinson is an expert in building, deploying and leading successful organizations from their earliest stages of development through their emergence as commercial enterprises and has successfully led multiple global businesses, operations and commercial ventures. A proven industry leader, Mr. Robinson served as a member of the Urovant Board of Directors prior to being appointed Urovants CEO in 2020. Mr. Robinson joined Astellas in 2005 as the Vice President of Health Systems, responsible for managed markets, reimbursement strategy, state government affairs and government accounts and has since held positions of increasing responsibility. In 2011, Mr. Robinson was named Senior Vice President of Sales and Marketing, leading the US organization responsible for sales, marketing, new product planning, market access and commercial operations. Mr. Robinson began his career at Schering-Plough in 1992 as a Sales Representative. He held positions of increasing responsibility until he was promoted to Vice President of Hepatitis Sales and managed care in 2003. Mr. Robinson led the largest specialty pharmaceutical sales division within Schering-Plough until he joined Astellas. He serves on the board of directors of MATTER. He serves a member of the BioScience council for ChicagoNEXT. Mr. Robinson served on the board of directors of Pharmaceutical Research and Manufacturers of America from 2013 to March 2018. He is member of The Commercial Club of Chicago. Mr. Robinson received a Bachelor of Science degree from DePaul University. He previously served on the Board of Directors for AGTC from 2021-2022 before the company was sold to Syncona LTD in December 2022.

Positions